BG106254A - Mag expression promoters - Google Patents

Mag expression promoters

Info

Publication number
BG106254A
BG106254A BG106254A BG10625401A BG106254A BG 106254 A BG106254 A BG 106254A BG 106254 A BG106254 A BG 106254A BG 10625401 A BG10625401 A BG 10625401A BG 106254 A BG106254 A BG 106254A
Authority
BG
Bulgaria
Prior art keywords
hypoplasia
expression promoters
mag expression
compounds represented
mag
Prior art date
Application number
BG106254A
Other languages
Bulgarian (bg)
English (en)
Inventor
Masakazu Kawasaki
Nobuharu GROTON
Yoshiharu Hayashi
Kazuyuki Kawasaki
Original Assignee
Mitsubishi Pharma Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Pharma Corporation filed Critical Mitsubishi Pharma Corporation
Publication of BG106254A publication Critical patent/BG106254A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BG106254A 1999-05-25 2001-12-20 Mag expression promoters BG106254A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP14433699 1999-05-25
PCT/JP2000/003373 WO2000071119A1 (fr) 1999-05-25 2000-05-25 Promoteurs de l'expression de la glycoproteine associee a la myeline (mag)

Publications (1)

Publication Number Publication Date
BG106254A true BG106254A (en) 2002-08-30

Family

ID=15359751

Family Applications (1)

Application Number Title Priority Date Filing Date
BG106254A BG106254A (en) 1999-05-25 2001-12-20 Mag expression promoters

Country Status (21)

Country Link
US (2) US7166630B2 (xx)
EP (1) EP1186296B1 (xx)
KR (1) KR100660955B1 (xx)
CN (1) CN1160072C (xx)
AT (1) ATE359780T1 (xx)
AU (1) AU774471B2 (xx)
BG (1) BG106254A (xx)
BR (1) BR0011551A (xx)
CA (1) CA2373967A1 (xx)
CZ (1) CZ20014203A3 (xx)
DE (1) DE60034448D1 (xx)
EE (1) EE200100621A (xx)
HK (1) HK1044721A1 (xx)
HU (1) HUP0201485A3 (xx)
IL (1) IL146726A0 (xx)
IS (1) IS6173A (xx)
MX (1) MXPA01012188A (xx)
NO (1) NO20015733L (xx)
NZ (1) NZ516261A (xx)
RU (1) RU2241454C2 (xx)
WO (1) WO2000071119A1 (xx)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE50214771D1 (de) 2002-04-20 2010-12-30 Haas Laser Gmbh & Co Kg Einrichtung zur Überwachung eines optischen Elements eines Bearbeitungskopfes einer Maschine zur thermischen Bearbeitung eines Werkstücks

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19541146A1 (de) * 1995-10-25 1997-04-30 Schering Ag Imidazolderivate und deren Verwendung als Stickstoffmonoxid-Synthase-Inhibitoren
IL125104A (en) * 1995-12-27 2002-12-01 Welfine Corp Pharmaceutical preparations for the prevention and treatment of diabetic complications containing acid 4 [a-hydroxy-2-methyl-5- (1-imidazolyl) benzyl] -5,3-benzoyl dimethyl, a compound with optical activity or hydrogen salt

Also Published As

Publication number Publication date
CA2373967A1 (en) 2000-11-30
CN1356900A (zh) 2002-07-03
WO2000071119A1 (fr) 2000-11-30
ATE359780T1 (de) 2007-05-15
AU4949700A (en) 2000-12-12
RU2241454C2 (ru) 2004-12-10
NO20015733L (no) 2002-01-11
IS6173A (is) 2001-11-23
MXPA01012188A (es) 2003-06-30
CZ20014203A3 (cs) 2002-06-12
DE60034448D1 (de) 2007-05-31
CN1160072C (zh) 2004-08-04
HUP0201485A2 (en) 2002-08-28
NO20015733D0 (no) 2001-11-23
NZ516261A (en) 2003-11-28
IL146726A0 (en) 2002-07-25
US20060270712A1 (en) 2006-11-30
EP1186296B1 (en) 2007-04-18
US7166630B2 (en) 2007-01-23
KR100660955B1 (ko) 2006-12-26
AU774471B2 (en) 2004-07-01
EP1186296A1 (en) 2002-03-13
HK1044721A1 (zh) 2002-11-01
US20050090531A1 (en) 2005-04-28
HUP0201485A3 (en) 2004-01-28
BR0011551A (pt) 2002-04-02
KR20020015332A (ko) 2002-02-27
EE200100621A (et) 2003-02-17
EP1186296A4 (en) 2004-12-22

Similar Documents

Publication Publication Date Title
EP0795548A4 (en) CHINAZOZINE DERIVATIVES AND THEIR USE
ES2102195T3 (es) Derivados heterociclicos de acido carbonico que se fijan en receptores de retinoides.
TR200000129T2 (tr) Yepyeni spiroazabisiklik heterosiklik bileşikler.
ES2174465T3 (es) Compuestos triazol y su utilizacion como ligandos de dopamina-d.
BG101112A (en) The use of heterocyclic compounds
PA8509301A1 (es) Inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en enfermedades inflamatorias, autoinmunes y respiratorias
BG105783A (en) Triazole compounds with dopamine-d3-receptor affinity
FI894911A0 (fi) En terapeutiskt vaerdefull foerening.
AU591860B2 (en) Pyrolidineamide derivative having anti-prolyl endopeptidase
ES2105108T3 (es) Esteroides para el tratamiento de la hipertrofia prostatica, su preparacion y su utilizacion.
MXPA02002452A (es) Agentes preventivos y terapeuticos para enfermedades de oftalmicas.
WO2005046672A3 (fr) Utilisation d’inhibiteurs de glucosidase pour une therapie de la mucoviscidose
RS50229B (sr) Analozi vitamina d3
ATE281161T1 (de) Heilmittel und vorbeugende mittel die cyclopentenonverbindungen als wirksamen stoff enthalten
BG106254A (en) Mag expression promoters
EP1374868A4 (en) MEDICAMENT FOR THE TREATMENT AND / OR PREVENTION OF DIABETIC ISCHEMIC DISEASES
AU2413399A (en) Combination of a ramba and a tocopherol
DE60034545D1 (de) Verwendung von chymase hemmern gegen vaskuläre lipidablagerung
AU5980094A (en) Morpholine derivative
HRP20010885B1 (en) Ethanesulfonyl-piperidine derivatives
ATE46156T1 (de) 1,3-benzoxathiol-derivate, deren verwendung und deren herstellung.
NZ216110A (en) 4-(z)-6-((2,4,5-cis -2-alkyl-4-(2-hydroxyphenyl)-1,3- dioxan-5-yl) hexenoic acid derivatives and pharmaceutical compositions
SE9704770D0 (sv) New use
ES2147499A1 (es) Derivados de acidos carboxilicos, metodo para su elaboracion y agentes terapeuticos que contienen estos compuestos.
AU1446892A (en) Novel oxa- or azasteroid derivative